TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in total-body BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder proprioception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to mortality
Endpoint domain: Mortality/survival
Primary endpoint: reduced scores on primary measures of mood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of hopelessness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: numbers of participants meeting Research Diagnostic Criteria for depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac mortality and morbidity
Endpoint domain: Mortality/survival
Primary endpoint: Percentage reduction in ESI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV‐1 RNA < 500 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of social isolation mentions
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Precision of NLP pipeline
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Recall of NLP pipeline
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: ACIC summary score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PACIC summary score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in chemiluminescence signal intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Lung overinflation measured as end-expiratory volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum attainable walking velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum phosphate reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reduction of intact FGF23 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: reduction of C-terminal FGF23 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Filling pressure estimate E/E' ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: E/A peak flow ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative incidences of healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in symptoms of initial discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of major vascular events
Endpoint domain: Mortality/survival
Primary endpoint: in-hospital mortality and/or heart transplantation
Endpoint domain: Mortality/survival
Primary endpoint: prolonged mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: prolonged hospital length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Numeric Pain Rating Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body temperature maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sodium ion concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in inflammatory acne lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in noninflammatory acne lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endurance performance times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of GVHD, grade 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in magnitude of SEQ at 4-6 weeks post-laser
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in magnitude of SEQ at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in CVD risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in HRQoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: rate of intra-abdominal abscess
Endpoint domain: Adverse events/effects
Primary endpoint: Abstinence from alcohol consumption
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of alcohol intoxication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of unprotected anal intercourse events
Endpoint domain: Life impact
Endpoint subdomain: Risk behaviors
Primary endpoint: Disease-Free Survival (DFS) rates
Endpoint domain: Mortality/survival
Primary endpoint: Physical Subscale of the Fatigue Impact Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Healing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Wound healing outcomes
Primary endpoint: Ethanol levels in blood and saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: renal-specific composite of end-stage kidney disease, doubling of creatinine level, or death from renal causes
Endpoint domain: Mortality/survival
Primary endpoint: end-stage kidney disease
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity to disease detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of anti-glaucomatous drugs used
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Lower back musculoskeletal discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ACL injury rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pain measured on a linear analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean reduction in attack rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular death, MI or stroke
Endpoint domain: Mortality/survival
Primary endpoint: Refractory angina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acceptability of randomisation to mode of delivery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to walk independently
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPAO score improvements
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HIV injecting risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sex risk composite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean head circumference gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean mid upper arm circumference gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTH reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Intra-reader reproducibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity to change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in skill levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of gram-negative organisms in infections
Endpoint domain: Adverse events/effects
Primary endpoint: posttreatment disability score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Risk of radiation-induced cancer
Endpoint domain: Mortality/survival
Primary endpoint: Mortality rate at 120 days
Endpoint domain: Mortality/survival
Primary endpoint: Modified Rankin Scale score at 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIH Stroke Scale improvement at 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: sensitivity of antifibrin scintigraphy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specificity of antifibrin scintigraphy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Total score on the problem-solving rubric
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: PSA doubling time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percentage of exacerbation-free patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EDSS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pupillary diameter measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of miosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High sensitivity C Reactive Protein (hsCRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postprandial gastric pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Shoulder internal rotation and horizontal adduction ROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle stiffness of the teres minor and infraspinatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: MVS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reaction time on the covert attentional processing task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Perinatal HIV transmission risk
Endpoint domain: Mortality/survival
Primary endpoint: Intrapartum HIV transmission risk
Endpoint domain: Mortality/survival
Primary endpoint: Peak OVA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total OVA excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: optimal hybridization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tubular seal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of cardiovascular diseases (CVDs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 50% or greater decrease in leakage and incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: reported zero stress incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: considered themselves cured or improved
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preference for CDF over ACD
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of CDF compared to ACD
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: nutritional performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in ferritin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Heart failure hospitalization or death
Endpoint domain: Mortality/survival
Primary endpoint: Total mortality associated with reduced eGFR
Endpoint domain: Mortality/survival
Primary endpoint: Cardiovascular events associated with reduced eGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Combined endpoint of ischemic complications and bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in tympanometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in audiometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ratio of CAM-D between generic clopidogrel and Plavix
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken off work for appointments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time spent on visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Shoulder pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal betaine excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum folate increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: RCF increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: morbidity after removal of lower third molars
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight at study end
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of infants less than the 10th percentile for length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of fat oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total bilirubin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for hospitalization or phototherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of severe jaundice
Endpoint domain: Adverse events/effects
Primary endpoint: vRVR rates
Endpoint domain: Mortality/survival
Primary endpoint: LDL cholesterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Recalcification rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of new bone metastasis formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Hypometabolism in cortical regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hemispheric asymmetry of hypometabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: rCBF/V(0) ratio change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: breast cancer risk reduction
Endpoint domain: Mortality/survival
Primary endpoint: Intrinsic foot muscle volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Vertical propulsive impulse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient perceived sensory peripheral neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient Neurotoxicity Questionnaire (PNQ) risk estimate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: phagocyte endocytic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ROS generation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PPAR‐γ expression in circulating monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean drain removal day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Daily drainage volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microcirculation of the superficial plexus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Oro-pharyngeal swallowing function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: weight loss at M6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality-adjusted life-year gained
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: increased life expectancy
Endpoint domain: Mortality/survival
Primary endpoint: proportion of children with virologic suppression at 48 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: distal colorectal adenoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bone gain after 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological new bone formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative peak levels of creatine kinase-MB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative brain natriuretic peptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) of simvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) of simvastatin acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak concentration (C(max)) of simvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak concentration (C(max)) of simvastatin acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: office blood pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Death or IQ <70
Endpoint domain: Mortality/survival
Primary endpoint: Pain self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: VLDL-C levels reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in apoA-II production rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: In-scaffold vasoconstriction response to endothelium-dependent stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: FcεRI receptor density on basophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Target vessel myocardial infarction
Endpoint domain: Adverse events/effects
Primary endpoint: Target lesion revascularization
Endpoint domain: Adverse events/effects
Primary endpoint: Median age of pubertal onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of pubertal pace
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postintervention knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Attitudes about suntanning
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: S‐metoprolol areas under the concentration vs. time curves
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metoprolol elimination half‐lives
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean S‐metoprolol/R‐metoprolol ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct demonstration of EpiPen use after 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct demonstration of Anapen use after 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Critical errors in administration of Anapen
Endpoint domain: Adverse events/effects
Primary endpoint: Bacterial growth in sutures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Ottawa scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk behaviors associated with substance use diagnoses
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: subjective physical health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Return to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual analog scores for mastalgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased interest in working in interventional cardiology and vascular surgery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Practical skills assessment for choosing a guidewire
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Confidence of trainees in their skills
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean difference between axillary and rectal temperatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variability in temperature measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ankle joint edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood loss after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 6-min walk task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bodily pain (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: general health (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status